Login to Your Account

Monitoring Committee Suspends Enrollment In QLT, Xenova Trial

By Kim Coghill

Monday, February 24, 2003
QLT Inc. agreed to temporarily suspend enrollment in two Phase III studies of tariquidar in non-small-cell lung cancer patients on advice of a monitoring committee, which reportedly noted some toxicity in the study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription